Riluzole pharmacokinetics in young patients with spinal muscular atrophy. - sprookjes - yvandenbroek - TriplyDB

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

http://www.wikidata.org/entity/Q34609016

about

Drug treatment for spinal muscular atrophy types II and III Drug treatment for spinal muscular atrophy types II and III New therapeutic approaches to spinal muscular atrophy.Spinal Muscular Atrophy Therapeutics: Where do we Stand?Therapy development for spinal muscular atrophy in SMN independent targets.Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.Riluzole Serum Concentration in Pediatric Patients Treated for Obsessive-Compulsive Disorder.

P2860

Q24200270-7BA22B9D-6406-48D8-A722-EDCBD73FA5DB Q24234414-49E1BC9E-B9D4-4BBB-BF42-406C132D2816 Q34237525-91235736-6B51-4786-9486-6A2729C8A63C Q34460251-38EA5FD4-5D28-4EBD-B93A-5D7E794D5FD1 Q36014761-E26C0803-01F7-4B5A-9866-1DF950629008 Q36095048-C40B9772-6167-4A55-ACDE-5A6894738615 Q42697702-FAD1C510-C2EA-4E42-A575-218EE96F9355

P2860

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

http://www.wikidata.org/entity/Q34609016

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@ast

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@en

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@nl

type

label

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@ast

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@en

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@nl

prefLabel

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@ast

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@en

Riluzole pharmacokinetics in young patients with spinal muscular atrophy.

@nl

P1433

Q34609016-32BB8D33-D6FA-4474-9883-D65295E24FD1

P1476

Q34609016-8293066A-5D65-4C8D-8FFF-29C778EC7D9C

P2093

Q34609016-0112AB09-6799-4B63-B3FE-334F523D6BFF

Q34609016-078D98AD-4EC7-4A15-BC1B-5904A9DFB5F6

Q34609016-3F97A47D-CBD7-436F-A5A9-4CC9E11C0C68

Q34609016-8612FF50-AC54-471F-B1FB-2563BAE25512

Q34609016-9BD906CA-29CC-411B-9460-304345BAE1FC

Q34609016-C601FDE9-A831-45CD-A3AC-7A74C5E5789A

Q34609016-C81EE99E-467F-4696-B9DD-AEEE82906789

Q34609016-F0139657-A8CD-46E1-81B3-ACB55B54DCF2

P2860

Q34609016-1D68BE46-F874-4993-8267-DD541C603E4A

Q34609016-23A7015E-7CD9-4B19-8133-077023734413

Q34609016-29D95EA7-1BCE-4883-894E-7B7679FC9776

Q34609016-32C40729-A784-45F0-9D35-199D46A3F23A

Q34609016-403E4C1E-5218-44BC-879A-4A3CEDCE6DC6

Q34609016-42EFB405-25FE-431A-A8A1-3F9CF5B63A81

Q34609016-473A8B02-99E2-45EF-9E04-E0563F322ED6

Q34609016-57415D4B-9619-4E5A-9BAB-A2BE25601991

Q34609016-96D65216-7773-4FC2-B0CE-0FE975A21B23

Q34609016-D63273D8-4AC4-41F5-BAB3-8A8A248DF00D

P304

Q34609016-91A87050-F87E-4850-9BC4-8ED91C521A67

P31

Q34609016-CF28758D-9C85-4937-8A6F-47E50DAA548A

P356

Q34609016-9000EA0A-6B39-4BC5-8D1A-DF3A9B08F9E9

P407

Q34609016-94476229-EA47-4E54-BC1A-687BBEF759A6

P433

Q34609016-0274A113-D95F-4654-9551-4BFDCABB5011

P478

Q34609016-466847D5-D6F9-4497-8926-CF222FDFEAA6

P50

Q34609016-5F89467B-6E3D-47AA-8571-8A35E27EF27C

P577

Q34609016-8CFF2F55-1445-46D6-8D68-EA2B9001E12F

P5875

Q34609016-477E0D37-8481-4EDE-AFCE-3C2D84596F8F

P698

Q34609016-4A7C129C-78B8-41B0-B23A-9E7E0654F25D

P921

Q34609016-14267007-8EB1-47C0-88E1-599F8310F910

P932

Q34609016-63669EDD-672A-48D4-BC25-1B23ECECC427

P356

J.1365-2125.2010.03843.X

P1433

British Journal of Clinical Pharmacology

P1476

Riluzole pharmacokinetics in young patients with spinal muscular atrophy

@en

P2093

Amal Ouslimani

http://www.w3.org/2001/XMLSchema#string

Annie Barois

http://www.w3.org/2001/XMLSchema#string

Bertrand Diquet

http://www.w3.org/2001/XMLSchema#string

Blandine Lehmann

http://www.w3.org/2001/XMLSchema#string

Brigitte Estournet

http://www.w3.org/2001/XMLSchema#string

Chadi Abbara

http://www.w3.org/2001/XMLSchema#string

Louis Viollet

http://www.w3.org/2001/XMLSchema#string

Lucette Lacomblez

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in plasma protein binding have little clinical relevance.

A phase 1 trial of riluzole in spinal muscular atrophy.

Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier.

Possible strategies for treatment of SMA patients: a neurobiologist's view.

Epidemiology of spinal muscular atrophies in a sample of the Italian population.

The pharmacology and mechanism of action of riluzole.

Phenotypic heterogeneity of spinal muscular atrophy mapping to chromosome 5q11.2-13.3 (SMA 5q).

Brain and plasma riluzole pharmacokinetics: effect of minocycline combination.

Riluzole attenuates spinal muscular atrophy disease progression in a mouse model.

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

P304

403-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2010.03843.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Benedicte Lelièvre

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49801629

http://www.w3.org/2001/XMLSchema#string

P698

21284699

http://www.w3.org/2001/XMLSchema#string

P921

spinal muscular atrophy

P932

3045549

http://www.w3.org/2001/XMLSchema#string